Group 1 - The core viewpoint of the article is that Shandong Xinde Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to expand its presence in the animal health market [1] - Shandong Xinde Technology was established in 1999 and is recognized as a leading animal health company in China [1] - The company engages in the research, production, and sales of a full range of animal health products, including veterinary biological products, traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives [1] Group 2 - According to the prospectus, Shandong Xinde Technology ranks ninth among domestic manufacturers in the Chinese animal health market based on projected revenue for 2024 [1] - The company is also ranked among the top three in the Chinese veterinary biological products market for poultry [1]

Company Overview - Shandong Xinde Technology Co., Ltd. is a leading animal health enterprise in China, established in 1999, focusing on the research, production, and sales of a full range of animal health products [3] - The company ranks ninth among domestic manufacturers in the Chinese animal health market, with a market share of 1.4% as of 2024 [4][12] - Its product offerings include veterinary biological products, traditional Chinese veterinary medicine, chemical drug formulations, animal feed, and feed additives [3] Business Model - The company operates on two core drivers: providing precise prevention and control solutions and leveraging innovation and production capabilities to deliver high-quality, cost-effective products [3][5] - It has established four production bases and 34 production lines certified by the new veterinary drug GMP [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately RMB 985 million, RMB 982 million, and RMB 878 million, respectively [6] - The net profit for the same periods was RMB 34.76 million, RMB 28.12 million, and RMB 55.67 million, respectively [7] - The gross profit margin improved from 49.7% in 2023 to 55.3% in 2025 [8] Industry Overview - The global animal health market was valued at USD 40.2 billion in 2019 and is projected to grow to USD 51.1 billion by 2024, with a CAGR of 4.9% [11] - The Chinese animal health market is expected to grow from RMB 509 billion in 2019 to RMB 680 billion by 2024, with a CAGR of 6.0% [12] Market Drivers - The increasing difficulty in animal disease prevention and control due to globalization and cross-border logistics has heightened the demand for effective animal health solutions [16] - The trend towards large-scale farming is evident, with the proportion of large-scale pig farming in China expected to rise from 50% in 2019 to 70% by 2024 [16] - There is a growing demand for pet health care driven by the increasing number of single-person households and an aging population in China [17]

据港交所2月16日披露，山东信得科技股份有限公司(简称：信得科技)向港交所主板递交上市申请书， 工银国际、中泰国际为其联席保荐人。根据灼识咨询的资料，以2024年收入计，该公司是在中国动物保 健市场中排名第九的国产厂商，并在中国禽用兽用生物制品市场排名前三。 据招股书，成立于1999年，该公司是中国领先的动物保健企业。该公司主要从事全系列动物保健及配套 产品的研发、生产及销售，产品涵盖兽用生物制品(如疫苗、抗体、转移因子等)、中兽药、化药制剂、 动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾病的预防、诊断、治疗与控制。 ...

智通财经APP获悉，据港交所2月16日披露，山东信得科技股份有限公司(简称：信得科技)向港交所主板 递交上市申请书，工银国际、中泰国际为其联席保荐人。根据灼识咨询的资料，以2024年收入计，该公 司是在中国动物保健市场中排名第九的国产厂商，并在中国禽用兽用生物制品市场排名前三。 据招股书，成立于1999年，该公司是中国领先的动物保健企业。该公司主要从事全系列动物保健及配套 产品的研发、生产及销售，产品涵盖兽用生物制品(如疫苗、抗体、转移因子等)、中兽药、化药制剂、 动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾病的预防、诊断、治疗与控制。 ...

瑞普生物做LP 导读： 上市公司密集设立并购基金，又一家LP入场。 作者丨黄蓉 时隔一年，瑞普生物又出手了。 2月12日，瑞普生物发布公告，称公司与海通并购（上海）私募基金管理有限公司、 海通开元投 资有限公司、高邮市产业引导基金（有限合伙）及关联方天津瑞晟私募基金管理有限公司签署《江 苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协议》，拟共同出资设立江苏国泰海通 瑞普并购产业基金合伙企业（有限合伙）。 根据公告，该基金总规模为人民币10亿元。其中，瑞普生物作为有限合伙人以自有资金及自筹资 金出资人民币2.95亿元，占合伙企业认缴出资总额的 29.50%。 此外， 作为有限合伙人， 海通开元出资2.05亿元，占认缴出资总额20.5%。高邮市产业引导基 金认购4.9亿元，占比49%。海通并 购（上海）私募基金管理有限公司作为基金普通合伙人和执 行事务合伙人，与 天津瑞晟私募基金管理有限公司各认缴500万元，占比0.5% 本基金投资期为5 年，退出期为2年。退出期后仍有存续项目的， 经合伙人会议同意可延长， 每 次不超过一年，最多不超过一次。 从投资方向看，此次产业并购基金主要以支持实体产业发展为导向，重 ...

经济观察网 普莱柯（603566）（603566）近期将召开临时股东大会，同时公司2025年业绩预告显示净 利润同比大幅增长。 近期事件 业绩经营情况 公司于2026年1月20日发布了2025年年度业绩预告，预计归属于上市公司股东的净利润为1.76亿元至1.95 亿元，同比增长89.64%到110.11%。正式年度报告尚未披露。 以上内容基于公开资料整理，不构成投资建议。 公司于2026年2月6日召开了第五届第二十三次董事会会议，审议了《关于召开2026年第一次临时股东会 的议案》等文件，表明可能在未来短期内召开临时股东大会。 ...

（编辑 丛可心） 证券日报网讯 2月12日，中牧股份在互动平台回答投资者提问时表示，公司及所属企业统一使用专业财 务软件，完成了公司财务核算，实现了财务数据的集中管理。通过财务数据统一规范，进一步提升数据 分析能力，促进公司准确掌握企业运营情况。目前公司正在积极推进信息系统的升级与融合，助力公司 未来长远发展。 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

Investment Rating - The report maintains an "Overweight" rating for the agricultural, forestry, animal husbandry, and fishery sector, indicating a positive outlook for the industry compared to the overall market performance [1][4]. Core Insights - The total net profit for the tracked companies in the agricultural, forestry, animal husbandry, and fishery sector is projected to be CNY 30.949 billion for 2025, reflecting a year-on-year decrease of 20%. The top three sub-sectors by profit growth are animal health (+76%), planting industry (+54%), and pet food (+3%) [3][4]. - The report highlights significant performance disparities among different sectors, with the animal husbandry sector facing challenges due to oversupply and declining prices, particularly in pig farming, where the average price of pigs dropped by 29.9% year-on-year [3][5]. - The pet food sector shows resilience in domestic markets despite a slowdown in overseas growth, with a projected online sales growth of 10.2% in 2025 [3][4]. Summary by Relevant Sections Animal Husbandry - The pig farming sector is expected to see a net profit of CNY 20.908 billion in 2025, down 26% year-on-year, with significant losses reported in Q4 [5][8]. - The chicken farming sector remains profitable, with white chicken prices stable and yellow chicken prices showing a 9.5% increase year-on-year [3][4]. Pet Food - Domestic pet food sales are projected to grow, with major companies like Guobao Pet and Zhongchong Co. expected to report net profits of CNY 0.678 billion and CNY 0.433 billion, respectively [3][4]. Planting Industry - The report notes a recovery in edible mushroom prices, with a projected net profit increase of 154% for Zhongxing Junye in 2025 [3][4]. - Blueberry prices have slightly decreased, but companies are expected to maintain profitability through volume sales [3][4]. Animal Health - The animal health sector is projected to see a net profit increase of 76%, driven by new product launches and increased demand for veterinary vaccines [3][4]. Seed Industry - The seed industry is facing challenges with low grain prices, leading to a mixed performance among companies, with Dabeinong expected to report a significant loss [3][4].